Stay updated on Pembrolizumab/Lenvatinib vs Docetaxel in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab/Lenvatinib vs Docetaxel in NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab/Lenvatinib vs Docetaxel in NSCLC Clinical Trial page
- Check3 days agoChange DetectedThe study history now shows the latest Revision: v3.6.3, replacing the previous Revision: v3.6.0.SummaryDifference0.0%

- Check10 days agoNo Change Detected
- Check18 days agoChange DetectedThe study record now shows recruitment is closed, indicating enrollment has ended. The revision history is updated with a new 'Revision: v3.6.0' entry and the previous 'Revision: v3.5.5' entry is removed.SummaryDifference0.1%

- Check26 days agoChange DetectedThe history now includes a new revision entry, v3.5.5, following the previous v3.5.4, representing an updated version of the page history.SummaryDifference0.0%

- Check47 days agoChange DetectedThe page's revision tag was updated from v3.5.3 to v3.5.4, indicating a new release/patch was applied. This update relates to site metadata rather than changes to study data or visible content.SummaryDifference0.0%

- Check69 days agoChange DetectedThe page now displays an updated “Revision” version number for the ClinicalTrials.gov interface (from v3.5.2 to v3.5.3). This represents a platform/version update rather than a modification to the trial record itself.SummaryDifference0.0%

- Check76 days agoChange DetectedAdded Revision: v3.5.2 and removed Revision: v3.5.0 in the history log.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab/Lenvatinib vs Docetaxel in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab/Lenvatinib vs Docetaxel in NSCLC Clinical Trial page.